Today's Rundown AstraZeneca creates $1B Chinese fund, vows to double R&D team After being bumped by BMS, ex-CSO Lynch lands as chair of Kleo Pharma Radius plans to cut loose oncology assets [Sponsored] Flip the Funnel: Rethinking Patient Recruitment and Enrollment Strategies Vifor commits €25M to nephrology R&D joint venture with Evotec A2 Biotherapeutics uncloaks with $57M and tumor-targeting cell therapies Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results Featured Story | | | Wednesday, November 6, 2019 AstraZeneca is stepping up its commitment to China, detailing plans to double the head count at its Shanghai R&D site and create a $1 billion investment fund. The initiatives build on the rapid growth AstraZeneca has achieved in China in recent years. |
|
|---|
|
Top Stories Wednesday, November 6, 2019 Amid the merger of Celgene and his former company Bristol-Myers Squibb, there was no room at the inn for oncologist Thomas Lynch, M.D., as its chief scientific officer. Wednesday, November 6, 2019 Radius says it will double down on osteoporosis and endocrine diseases as looks to offload its cancer work. Monday, November 4, 2019 No matter how successful advertising campaigns are, all that really matters is how many referrals ultimately participate in the trial. It’s time to flip the funnel and focus on converting recruits into enrollees. Wednesday, November 6, 2019 Vifor Pharma has committed €25 million ($28 million) to a nephrology joint venture with Evotec. The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor. Tuesday, November 5, 2019 Another cancer-focused startup is joining the fray—A2 Biotherapeutics is launching with $57 million in series A cash to pursue cell therapies for solid tumors, an area in which CAR-T treatments and their ilk have run into difficulties. The funding comes from the likes of The Column Group, Vida Ventures, Samsara BioCapital and Nextech Invest. Wednesday, November 6, 2019 Thermo Fisher Scientific has launched a new, automated next-generation sequencing platform, designed to turn around results from specimens in a single day—which the company says will help give smaller, local hospitals a better chance at offering high-throughput genomic testing. Enrollment Showcase Resources Sponsored by: SHYFT Analytics This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow. Sponsored by: IBM Watson Health Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more. Sponsored by: ON24 Discover solutions to the most common challenges faced by medical device companies. Sponsored by: Eli Lilly and Company in partnership with Xcenda Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system. Sponsored by: Clarivate Analytics 18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: BBK Worldwide Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app. Sponsored by: Blue Latitude Health Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve Sponsored by: Article Galaxy powered by Reprints Desk This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy. Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA A Rare Affair for Rare Diseases January 12, 2020 | San Francisco, CA | 